CB2 Insights Announces New Appointment to Board of Directors with Medical Cannabis and Capital Markets Executive

NEXT STORY
I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of the CD73 Antibody TJD5 in Patients with Advanced Solid Tumors
PREV STORY
Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights

One-time treatment with VY-AADC demonstrates durable improvements in motor function at 18 months and ...

author_avatar
NASDAQ Market News

Owkin Enters Into Agreement to Build Innovative Methods With the Potential to Enhance AI-Enabled External Control Arms

author_avatar
NASDAQ Market News

Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent

author_avatar
NASDAQ Market News